Clinical trials: Sjogren's Syndrome, active
Healthy Volunteer, Sjogren's Syndrome
Characterization of Diseases With Salivary Gland Involvement
Background: Salivary glands in and around the mouth and throat make saliva. Salivary gland disorders can affect a person s quality of life.
- Conditions
- Healthy Volunteer, Sjogren's Syndrome, Salivary Gland Disease
- Trial name
- NCT02327884
- Where
- United States
- Volunteers
- 1,150 people, healthy volunteers welcome
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Sjögren's Syndrome
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE
rhPRG4-Sjögren's-002 is a prospective multi-center study conducted in Australia to evaluate the safety and efficacy of topically-applied rhPRG4 in subjects with Sjögren's related Dry Eye Disease.
- Trial name
- NCT07118241
- Testing
- Recombinant Human Proteoglycan 4, Vehicle Control
- Where
- 7 sites in Australia
- Volunteers
- 80 people
- Sponsor
- Lubris Bio Pty Ltd
Primary Sjögren Syndrome, Sarcopenia
Possible Sarcopenia, Sarcopenia, and Functional Status in Patients With Primary Sjögren's Syndrome
The aim of this study is to evaluate the frequency of probable sarcopenia and sarcopenia in patients with primary Sjögren syndrome and to investigate the effects of sarcopenia on functional status, muscle strength, and quality of…
- Trial name
- NCT07804719
- Testing
- dexa, hand grip strength, myostatin, follistatin
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Antalya Training and Research Hospital
Rheumatic Diseases, Lupus Erythematosus, Systemic
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Background: Rheumatic diseases can affect the joints, ligaments, tendons, bones, muscles, and skin. They can also cause inflammation, damage body tissues, and change nerve signals in the brain.
- Conditions
- Rheumatic Diseases, Lupus Erythematosus, Systemic, Lupus Vasculitis, Central Nervous System, Arthritis
- Trial name
- NCT07829497
- Testing
- Bedside quantitative sensory testing
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Systemic Lupus Erythematosus, Systemic Sclerosis
An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
An exploratory clinical study of the safety and efficacy of YTS109 cell injection in subjects with recurrent/refractory autoimmune disease
- Conditions
- Systemic Lupus Erythematosus, Systemic Sclerosis, Inflammatory Myopathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- NCT06379646
- Testing
- YTS109
- Where
- China
- Volunteers
- 6 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Inflammatory Myopathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- NCT06978647
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 12 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
GVHD, Meibomian Gland Dysfunction (Disorder)
Autologous Serum Obtained by a Closed-Circuit Collection Device
Autologous serum eye drops (ASED) are an established therapy for ocular surface diseases; however, their preparation can be costly and may not be available due to the need for germ-free conditions.
- Conditions
- GVHD, Meibomian Gland Dysfunction (Disorder), Stevens-Johnson Syndrome, Limbal Keratoconjunctivitis
- Trial name
- NCT07014059
- Testing
- Autologous Serum 20%
- Where
- Brazil
- Volunteers
- 16 people
- Sponsor
- GIANCARLO FATOBENE
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and SLE-ITP, Sjogren's Syndrome, etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Sjogren's Syndrome (SS), Inflammatory Myopathy
- Trial name
- NCT07123519
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Healthy Participants Study, Rheumatoid Arthritis
A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical activity of CND319 in healthy adult participants and patients with rheumatic diseases.
- Conditions
- Healthy Participants Study, Rheumatoid Arthritis, Sjogren's Syndrome
- Trial name
- NCT07712939
- Testing
- CND319
- Where
- Australia
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Candid Therapeutics
Sjogren's Syndrome
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease
Background: Sjogren disease is an autoimmune disease - that is, a disease that causes the body's immune system to attack its own organs and tissues. Sjogren disease can affect the kidneys, lungs, or other organs.
- Trial name
- NCT07281456
- Testing
- Tofacitinib
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Primary Sjogren's Disease
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease (UPSTREAM SjD)
- Trial name
- UPSTREAM SjD (NCT07404865)
- Testing
- Telitacicept
- Where
- 49 sites in United States, Georgia
- Volunteers
- 250 people
- Sponsor
- Vor Biopharma
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome (SS)
A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
This is an open-label, dose escalation study in patients with relapsed and refractory autoimmune diseases. Study drug, TI-0032-III injection, is composed of lipid nanoparticles (LNPs) targeting T cells that encapsulate circular…
- Conditions
- Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome (SS), Systemic Sclerosis (SSc), Inflammatory Myopathy
- Trial name
- in vivo CAR-T (NCT07413341)
- Testing
- TI-0032-III injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Therorna
Primary Sjögren Syndrome
A Study of RSLV-132 in Females With Sjögren's Disease
The goal of this clinical study is to learn if RSLV-132 improves the symptoms of SS in adults. It will also learn about the safety of RSLV-132.
- Trial name
- NCT06440525
- Testing
- RSLV-132
- Where
- 24 sites in United States
- Volunteers
- 106 people
- Sponsor
- Resolve Therapeutics
Sjogrens Syndrome
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
The purpose of this study is to measure the long-term safety and tolerability of ianalumab in participants with Sjögren's syndrome who have previously completed treatment from one of two NEPTUNUS 1 year core studies (CVAY736A2301…
- Trial name
- NEPTUNUS-Ext (NCT05985915)
- Testing
- Ianalumab (VAY736)
- Where
- 198 sites in United States, Argentina and 33 more
- Volunteers
- 612 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus, Sjögren's Disease
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07873931
- Testing
- BMS-986553
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Sjogren's Syndrome, Salivary Gland
The Pathogenesis and Natural History of Sjogren's Disease
Background: -Sjogren s Disease (formerly: Sjogrens Syndrome, Sj(SqrRoot)(Delta)gren s syndrome) is a disease that affects about 1-4 million Americans. It is more common in women.
- Conditions
- Sjogren's Syndrome, Salivary Gland, Pathogenesis
- Trial name
- NCT01425892
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Sjögren´s Disease
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
The purpose of this study is to demonstrate the efficacy and safety of ianalumab (VAY736) 300 mg administered subcutaneously (s.c.) monthly for 52 weeks in adult participants with Sjögren's disease who have high symptom burden.
- Trial name
- THALASSA (NCT07621809)
- Testing
- VAY736
- Where
- 33 sites in United States, Australia and 6 more
- Volunteers
- 570 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis, Systemic Lupus Erythematosus
A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body
This first-in-human study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of HBM7020.
- Conditions
- Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Sjögren's Disease
- Trial name
- NCT07649265
- Testing
- HBM7020
- Where
- Australia
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Sjögren's Disease
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
To evaluate efficacy, safety, and tolerability of DDY391 up to 52 weeks in participants with Sjögren's disease (SjD) and to determine the dose response relationship of DDY391 in participants with SjD, to support dose selection…
- Trial name
- NCT07737743
- Testing
- DDY391
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 344 people
- Sponsor
- Novartis Pharmaceuticals
Sjogren Syndrome
Effectiveness of an Oral Exercise Program for Xerostomia in Patients With Sjögren Disease
Sjögren disease (SjD) is a chronic autoimmune disease in which salivary gland dysfunction commonly causes persistent dry mouth (xerostomia).
- Trial name
- NCT07864987
- Testing
- Oral exercise
- Volunteers
- 56 people
- Sponsor
- Nazli Elif Nacar